Redeye comments on Xspray following an undramatic Q1 report. The key focus remains on the ongoing regulatory process and launch preparations for Dasynoc, alongside the continued clinical development of XS003.
ANNONS
Redeye comments on Xspray following an undramatic Q1 report. The key focus remains on the ongoing regulatory process and launch preparations for Dasynoc, alongside the continued clinical development of XS003.
